Al's Comment:

 This is the peer reviewed publication of the DCVAX trial that we have been waiting for!   Same excellent results that we reported in May but they go into details such as how the external control arm was constructed to account for all of the variables including the fact that the DCVAX trial rejected patients who progressed quickly during radiation.  I feel the article responds very well  to every critisism I heard from the May report..  And it was published in a high impact Journal - JAMA Oncology which has an impact factor of 33, where anything over a 10 is considered "excellent"!

Posted on: 11/17/2022

Association of Autologous Tumor Lysate Loaded Dendritic Cell Vaccination With Extended Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma


Click HERE to return to brain tumor news headlines.

Our privacy / cookie policy has changed.
Click HERE to read it!